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Natural Killer T cell-based immunotherapy for cancer 
Jaume Vila Gatius 
Cancer is one of the most threatening diseases nowadays and 
immunotherapy is a successful field of research. Therefore, oncology 
immunotherapy has become a potential source of investigation, and its 
main results are related to cell therapy and monoclonal antibodies 
My work is based on cell therapy, specifically, on Natural Killer T cells 
2. Natural Killer T cells 
4. Conclusions 
• Immunosupressive TME eradicates antitumor responses 
• Small NKT population, which is even lower in cancer patients, is associtaed 
with worse prognosis 
• All studies are small scale trials without long monitoring 
• Differences between mouse and human in CD1d and iNKT frequencies  
• Novel: reserach in humanized mouse models, αGC analogs, delivery vectors 
• Trials with mature DCs or PBMCs have shown better results than DCs 
• Combination immunotherapy is not as good as expected theorically 
• Irradiated tumor approaches are the best candidate for vaccination 
 
• Novel 
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1. Introduction 
Features Type I (iNKT) Type II (vNKT) 
TCR α chain Vα24Jα18 Diverse 
TCR β chain Vβ11 (and others) Diverse 
Subsets 
(coreceptors) 
CD4- CD8- (DN) 
CD4+ 
CD8+ 
CD4- CD8- (DN) 
CD4+ 
γδ T cells 
Antigens Glycolipid (α-GalCer)  Sulfatide moieties  
Main role in cancer Enhance immune response 
Suppress immune 
response  
To describe NKT functions and roles in tumor immunity 
To take a deep look into current NKT cell-based therapies 
To analyze relevant clinical trials and future directions 
Antigen-CD1d complexes recognition 
They express TCR and NK receptors 
They develop and mature in the thymus 
Characteristics 
Tumor immunity 
3. NKT cell-based 
immunotherapy of cancer 
- Free α-GalCer injection 
 
It activates antitumor immune responses directed by iNKT cells, but it shows 
conflicting effects as it induces Th-0-like cell responses (cytokine mix) 
Therapy 
objectives 
Elimination of MHC +/- cells in order to avoid tumor relapse 
Use of adjuvants as tumor cells are low immunogenic 
To induce DC maturation to promote efficient responses 
Hydrophobic  pro-inflammatory, Th-1 cytokines 
Solubility  anti-inflammatory, Th-2 cytokines 
Toleration, safety and transient increase of NKT cells have 
been observed but it also has shown inefficient immune 
responses with a long period of anergy 
Trial 
outcomes 
- Autologous DCs loaded ex vivo with α-GalCer 
 
It increases iNKT cell expansion and its INF-γ production. Moreover, it is 
tolerated and less likely to generate anergy of iNKT cells than a plain α-GalCer 
injection. Finally, various routes of administration have been successful 
- Tumor cells loaded with α-GalCer 
 
It has high specificity, yet it  
needs adjuvants so as to be  
effective 
 
 
 
                         IFN-γ route enhancement: activation of iNKT, NK and CTL 
 
Novel: Immune memory after its combination with anti-4-1BB Ab reported 
 - Other α-GalCer immunotherapies 
 
Anti-PDL1 Ab: it promotes iNKT Th-1 cytokine production and NK activation 
Anti-ganglioside GD2 Ab: it shows iNKT-NK interaction and enhancement 
Antibody + CD1d/αGC complexes: they induce tumor-specific CTL activation 
Live bacteria as αGC vector: it activates tumor-specific CTL 
- Ex vivo expansion of autologous iNKT cells 
- Combination immunotherapy 
 
Ex vivo expanded autologous iNKTs and α-GalCer-pulsed DCs 
Cancer Immunotherapy 
CD1d +  αGC-loaded tumor cells  
CD1d –  αGC + cross-presentation 
Trial  
outcomes 
Toleration and no severe side effects reported 
It shows moderated responses in NKT and NK cell activities 
It induces partial response, stable disease and tumor regression 
Toleration and safety 
Disease stabilization 
No tumor regression 
Trial  
outcomes 
IFN-γ-producing PBMCs 
DN or CD8+ NKT  Th-1 cytokines 
Dependable on initial NKT frequency 
activated 
NKTs 
+ α-GalCer  
+ IL-2 
Trial  
outcomes 
iPS: reinfusion of larger numbers of NKT promotes CTL activation 
CARs: NKT transduced with CAR.GD2 induces persistent activity 
Tumor size and necrosis reduction have been observed  
It has shown disease stabilzation in some cases 
Figure 1: Altman J. et al. Journal of Immunology Research. 2015. 
Figure 2: Motohashi S. et al. Cancer Science. 2008. 
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Trial  
outcomes 
α-GalCer analogs 
Objectives 
